April 2002

Chris Snell — Enjoying the Ride

October 23, 2009

Many dream of forming their own business, one that would blos som into a highly successful company without losing sight of its vivac ity. Chris Snell — president of creative services at inChord Communications Inc., and a founding partner of Gerbig, Snell/Weisheimer & Associates, now a division of inChord — is one of those rare […]

The Nose Knows

October 23, 2009

Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceuticals Ltd., a U.K.based niche pharmaceuti cal company is […]

Planting the Seeds of a Blockbuster

October 23, 2009

Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing and manufacturing. In 2000, biotech companies saw their bank accounts increase exponentially as venture […]

Coming Into Focus

October 23, 2009

The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according to data from IMS Health. There are no Japanese companies in the […]

Beyond the Genome — Proteomics

October 23, 2009

Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February 2001, it quickly became […]

Talent Pool

October 23, 2009

Biotech POOL Dr. Miguel S. BARBOSA Chugai Biopharmaceuticals hires VPof discovery biology to lead drug discovery efforts Chugai Biopharmaceuticals Inc., a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., has appointed Miguel S. Barbosa, Ph.D., as VP of discovery biology. Dr. Barbosa is charged with leading the direction and operation of the company’s drugdiscovery programs, […]

E-Media

October 23, 2009

NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES etrials Inc., a preferred partner for innovative data management technologies and services for the healthcare industry, has formed a joint marketing agreement to integrate and cross sell technology with DataScout Software Inc., a premier provider of innovative, regulatory compliant interactive voiceresponse (IVR) software solutions. The alliance enables […]

What’s New

October 23, 2009

Expanding its offerings, inChord Communications Inc., one of the largest independent healthcare mar keting communications companies in the world, has established a new organization — Y Brand Outlook — that will offer strategic consulting and branding services. Based in New York City,Y Brand Out look is led by Vince Parry, who recently left his posi […]

PharmaTrax

October 23, 2009

$7 Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS by 2005 The market for drugs employing advanced drug delivery technologies will surpass $7 billion by 2005,according to a study from Kalorama Information.The market segment has seen doubledigit growth over the past few years, and analysts predict that this trend should continue. Moreover,The Market for […]

For Art’s Sake

October 23, 2009

CREATIVE review I remember the first time I saw this ad whilst still working in Sydney. It caused plenty of discussion. Great work connects, and does it quickly. I wish I’d done this one. Having been in healthcare for plenty of years, I’ve seen my share of dissection, so let’s take a crack at pulling […]

Pharma Outlet

October 23, 2009

Despite a history of new product launches, strong growth, and increased research spending, it is clear that the pharmaceutical industry is in a period of major transition. The challenge facing the industry is one of creating a sustainable pipeline that can generate the longterm growth needed to fuel the sector. This challenge faces both the […]

What’s on your mind: Opinions

October 23, 2009

Platform Data Intelligent guidelines regarding use of physician prescribing profiles would have a minimal impact on pharmaceutical marketing. It should be noted that such data acquired by pharmaceu tical companies from pharmacies, third party syndicators, and the American Medical Association Physician Professional Data are primarily used as merely platforms upon which such pro file data […]

Raise Your Voice: Letters

August 13, 2009

Pricing: At What Cost In your March 2002 article “The Cost of Doing Business,” I criticized as incorrect the conclusion that high R&D costs cause high pharma prices. A more economically sensible conclusion is that high pharma prices cause companies to undertake higher cost, more diffi cult, and risky research. Regrettably, I attribut ed the […]

Letter from the Editor

August 13, 2009

PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Diane Hoffman Virginia Kirk Denise Myshko Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, Number Three PharmaVoice is published eight times per year by PharmaLinx LLC, P.O.Box […]

FEEDBACK